Yang et al.[224] proposed a multifunctional nanogel system (HCSC‐gel) that combines the enzymatic degradation of collagenase (CN), PDT, and STING agonist‐mediated immunotherapy to overcome tumor penetration barriers and immunosuppression in breast cancer treatment and achieve synergistic treatment of primary and metastatic lesions. The gene discussed is STING1; the disease is neoplasm.